Cargando…

Six Serum miRNAs Fail to Validate as Myotonic Dystrophy Type 1 Biomarkers

Myotonic dystrophy type 1 (DM1) is an autosomal dominant genetic disease caused by expansion of a CTG microsatellite in the 3’ untranslated region of the DMPK gene. Despite characteristic muscular, cardiac, and neuropsychological symptoms, CTG trinucleotide repeats are unstable both in the somatic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fernandez-Costa, Juan M., Llamusi, Beatriz, Bargiela, Ariadna, Zulaica, Miren, Alvarez-Abril, M. Carmen, Perez-Alonso, Manuel, Lopez de Munain, Adolfo, Lopez-Castel, Arturo, Artero, Ruben
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4769077/ https://www.ncbi.nlm.nih.gov/pubmed/26919350 http://dx.doi.org/10.1371/journal.pone.0150501

Ejemplares similares

Muscleblind, BSF and TBPH are mislocalized in the muscle sarcomere of a Drosophila myotonic dystrophy model
por: Llamusi, Beatriz, et al.
Publicado: (2013)

Modeling of Myotonic Dystrophy Cardiac Phenotypes in Drosophila
por: Chakraborty, Mouli, et al.
Publicado: (2018)

Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model
por: Bargiela, Ariadna, et al.
Publicado: (2015)

Defined d-hexapeptides bind CUG repeats and rescue phenotypes of myotonic dystrophy myotubes in a Drosophila model of the disease
por: Rapisarda, Anna, et al.
Publicado: (2021)

Social cognition in myotonic dystrophy type 1: Specific or secondary impairment?
por: Labayru, Garazi, et al.
Publicado: (2018)

MicroRNA-Based Therapeutic Perspectives in Myotonic Dystrophy
por: López Castel, Arturo, et al.
Publicado: (2019)

Age‐related cognitive decline in myotonic dystrophy type 1: An 11‐year longitudinal follow‐up study
por: Labayru, Garazi, et al.
Publicado: (2019)

Derepressing muscleblind expression by miRNA sponges ameliorates myotonic dystrophy-like phenotypes in Drosophila
por: Cerro-Herreros, Estefania, et al.
Publicado: (2016)

Myotonic dystrophy type 1 drug development: A pipeline toward the market
por: Pascual-Gilabert, Marta, et al.
Publicado: (2021)

Quantitative magnetic resonance imaging assessment of muscle composition in myotonic dystrophy mice
por: Bargiela, Ariadna, et al.
Publicado: (2023)

Shedding light on motor premanifest myotonic dystrophy type 1: A molecular, muscular and central nervous system follow‐up study
por: Garmendia, Joana, et al.
Publicado: (2022)

miR-7 Restores Phenotypes in Myotonic Dystrophy Muscle Cells by Repressing Hyperactivated Autophagy
por: Sabater-Arcis, Maria, et al.
Publicado: (2019)

Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1
por: Labayru, Garazi, et al.
Publicado: (2019)

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2020)

Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies
por: Espinosa-Espinosa, Jorge, et al.
Publicado: (2022)

Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1
por: García-Alcover, Irma, et al.
Publicado: (2014)

Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
por: Cerro-Herreros, Estefanía, et al.
Publicado: (2021)

Expanded CCUG repeat RNA expression in Drosophila heart and muscle trigger Myotonic Dystrophy type 1-like phenotypes and activate autophagocytosis genes
por: Cerro-Herreros, Estefania, et al.
Publicado: (2017)

Pentamidine rescues contractility and rhythmicity in a Drosophila model of myotonic dystrophy heart dysfunction
por: Chakraborty, Mouli, et al.
Publicado: (2015)

Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSA(LR) Mice
por: Álvarez-Abril, Mari Carmen, et al.
Publicado: (2023)

Senescence plays a role in myotonic dystrophy type 1
por: García-Puga, Mikel, et al.
Publicado: (2022)

Two Enhancers Control Transcription of Drosophila muscleblind in the Embryonic Somatic Musculature and in the Central Nervous System
por: Bargiela, Ariadna, et al.
Publicado: (2014)

Targeting Myotonic Dystrophy Type 1 with Metformin
por: García-Puga, Mikel, et al.
Publicado: (2022)

Musashi-2 contributes to myotonic dystrophy muscle dysfunction by promoting excessive autophagy through miR-7 biogenesis repression
por: Sabater-Arcis, Maria, et al.
Publicado: (2021)

Leukocyte telomere length in patients with myotonic dystrophy type I: a pilot study
por: Wang, Youjin, et al.
Publicado: (2019)

Daunorubicin reduces MBNL1 sequestration caused by CUG-repeat expansion and rescues cardiac dysfunctions in a Drosophila model of myotonic dystrophy
por: Chakraborty, Mouli, et al.
Publicado: (2018)

miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models
por: Cerro-Herreros, Estefania, et al.
Publicado: (2018)

In silico discovery of substituted pyrido[2,3-d]pyrimidines and pentamidine-like compounds with biological activity in myotonic dystrophy models
por: González, Àlex L., et al.
Publicado: (2017)

Muscle wasting in myotonic dystrophies: a model of premature aging
por: Mateos-Aierdi, Alba Judith, et al.
Publicado: (2015)

Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
por: Overby, Sarah J., et al.
Publicado: (2022)

Myotonic Dystrophy type 1 cells display impaired metabolism and mitochondrial dysfunction that are reversed by metformin
por: García-Puga, Mikel, et al.
Publicado: (2020)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I
por: Koehorst, Emma, et al.
Publicado: (2020)

BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSA(LR) Mice
por: Overby, Sarah J., et al.
Publicado: (2023)

Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration
por: Jimenez‐Marin, Antonio, et al.
Publicado: (2021)

Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
por: González-Martínez, Irene, et al.
Publicado: (2023)

Molecular Effects of the CTG Repeats in Mutant Dystrophia Myotonica Protein Kinase Gene
por: Llamusí, Beatriz, et al.
Publicado: (2008)

Myotonic dystrophy
por: Patterson, VH
Publicado: (1990)

rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
por: Sellier, Chantal, et al.
Publicado: (2018)

Cancer and Myotonic Dystrophy
por: D’Ambrosio, Eleonora S., et al.
Publicado: (2023)

Delay of EGF-Stimulated EGFR Degradation in Myotonic Dystrophy Type 1 (DM1)
por: Alegre-Cortés, Eva, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tbog9umn6503s3k5s76lpoq9or